Analysis of p53/BAX in primary colorectal carcinoma: Low BAX protein expression is a negative prognostic factor in UICC stage III tumors

International Journal of Cancer

Volumn 99, Issue 4, 2002, Pages 589-596

  Schelwies, Katharina ^a   Sturm, Isrid ^a   Grabowski, Patricia ^b   Scherübl, Hans ^b   Schindler, Isabell ^b   Hermann, Sandra ^a   Stein, Harald ^b   Buhr, Heinz Johannes ^b   Riecken, Ernst O ^b   Zeitz, Martin ^b   Dörken, Bernd ^a   Daniel, Peter T ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Apoptosis; BAX; Bcl 2; Colorectal cancer; p53; Survival

Indexed keywords

PROTEIN BAX; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECTUM CARCINOMA; RETROSPECTIVE STUDY;

EID: 0036605086     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10380     Document Type: Article

References (47)

1. Cancer of the colon
2. Tumoren des Gastrointestinaltraktes. Kolorektales karzinom
3. Dissecting the pathways to death
4. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
5. Bcl-2 family members and the mitochondria in apoptosis
6. Tumour genotype and response to cytotoxic gene therapy
7. The kiss of death: Promises and failures of death receptors and ligands in cancer therapy
8. The most unkindest cut of all: On the multiple roles of mammalian caspases
9. Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cells with acquired drug resistance
10. Cytochrome c and dATP-dependent formation of Apaf1/caspase-9 complex initiates an apoptotic protease cascade
11. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo
12. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies
13. Analysis of the p53/BAX pathway in colorectal cancer: Low BAX is a negative prognostic factor in patients with resected liver metastases
14. Prognostic significance of BAX protein expression in diffuse aggressive non-Hodgkin lymphoma
15. BAX protein expression and clinical outcome in epithelial ovarian cancer
16. Bax, but not bcl-2, influences the prognosis of human pancreatic cancer
17. ink4a/CDKN2 identifies patients with good prognosis
18. Induction of the death-promoting gene bax-α sensitizes cultured breast-cancer cells to drug-induced apoptosis
19. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia
20. TP53 and long-term prognosis in colorectal cancer: Mutations in the L3 zinc-binding domain predict poor survival
21. p53 point mutation and survival in colorectal cancer patients
22. Association of p53 mutations with short survival in colorectal cancer
23. Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma
24. Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma
25. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer and its prognostic significance
26. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma
27. p53 point mutation and survival in colorectal cancer patients: Effect of disease dissemination and tumour location
28. p53 and PCNA expression in advanced colorectal cancer: Response to chemotherapy and long-term prognosis
29. p53 and Rb1 protein expression: Are they prognostically useful in colorectal cancer?
30. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation
31. Neuroendocrine differentiation is a relevant prognostic factor in Stage III-IV colorectal cancer
32. Impaired BAX protein expression in breast cancer: Mutational analysis of the BAX and the p53 gene
33. BAX expression in benign and malignant thyroid tumors: Dysregulation of wildtype p53 is associated with a high BAX and p21 expression in thyroid carcinoma
34. p53, the cellular gatekeeper for growth and division
35. One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element
36. DNA microarrays identification of primary and secondary target genes regulated by p53
37. Database of p53 gene somatic mutations in human tumors and cell lines
38. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis
39. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition
40. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis
41. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane
42. Bax deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis
43. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance
44. Bcl-2 protein expression: Association with p53 and prognosis in colorectal cancer
45. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma
46. Immunohistochemical detection of p53 and Bc1-2 in colorectal carcinoma: No evidence for prognostic significance
47. Immurohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors and ras protein product in colorectal adenomas, carcinomas and adjacent nonneoplastic mucosa